東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Anatomical and Functional Neuroprote...

Sharma, Sripadh.

FindBook

Google Book

Amazon

博客來

Anatomical and Functional Neuroprotection in Traumatic Brain Injury.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Anatomical and Functional Neuroprotection in Traumatic Brain Injury./
作者:	Sharma, Sripadh.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	225 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-07, Section: B.
Contained By:	Dissertations Abstracts International81-07B.
標題:	Neurosciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22617345
ISBN:	9781392402788

Anatomical and Functional Neuroprotection in Traumatic Brain Injury.
Sharma, Sripadh.

Anatomical and Functional Neuroprotection in Traumatic Brain Injury. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 225 p.

Source: Dissertations Abstracts International, Volume: 81-07, Section: B.

Thesis (Ph.D.)--Northwestern University, 2019.

This item is not available from ProQuest Dissertations & Theses.

Traumatic brain injury (TBI) is a major cause of disease and disability with no disease modifying surgical or medical treatment in existence. The secondary damage, a part of the body's natural inflammatory response to the initial injury, mediates formation of many of the sequela and life- threatening aspects of moderate to severe TBIs. In this monograph, we investigate an acute pharmacologic therapeutic intervention for TBI using immunomodulatory nanoparticles (IMPs). IMPs ablate a specific subset of hematogenous monocytes (hMos) that, in part, mediate secondary damage after TBI. We show that IMPs have a specific mechanism of action not only by ablating hMos but also by changing the number and phenotype of the immune cells that mediate secondary damage to be more M2/anti-inflammatory. We also show that IMPs protect and preserve brain matter after TBI, and, with this neuroprotection, the neural physiology and functional behavior is greatly preserved. Furthermore, IMPs, an FDA-approved material, are biodegradable, shelf-stable, and extremely easy to administer by emergency first-responder teams which makes it a very attractive clinically translational therapeutic. Finally, we briefly describe the beginnings of a study showing novel interplay of YAP/TAZ and micro-RNAs 21 and 29b in the pathophysiology of CNS injuries using IMPs to dissect these interactions. We are currently conducting further studies to expound the mechanism of IMPs in TBI so that we can start Phase I clinical trials for the first potential disease-modifying acute intervention for TBI.

ISBN: 9781392402788Subjects--Topical Terms:

588700
Neurosciences.
Subjects--Index Terms:

Brain

Anatomical and Functional Neuroprotection in Traumatic Brain Injury.
LDR:02954nmm a2200421 4500 001 2272751
005 20201105110214.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392402788
035 $a (MiAaPQ)AAI22617345
035 $a AAI22617345
040 $a MiAaPQ $c MiAaPQ
100 1 $a Sharma, Sripadh. $3 3550177
245 1 0 $a Anatomical and Functional Neuroprotection in Traumatic Brain Injury.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 225 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-07, Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisor: Kessler, John;Varga, John.
502 $a Thesis (Ph.D.)--Northwestern University, 2019.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a Traumatic brain injury (TBI) is a major cause of disease and disability with no disease modifying surgical or medical treatment in existence. The secondary damage, a part of the body's natural inflammatory response to the initial injury, mediates formation of many of the sequela and life- threatening aspects of moderate to severe TBIs. In this monograph, we investigate an acute pharmacologic therapeutic intervention for TBI using immunomodulatory nanoparticles (IMPs). IMPs ablate a specific subset of hematogenous monocytes (hMos) that, in part, mediate secondary damage after TBI. We show that IMPs have a specific mechanism of action not only by ablating hMos but also by changing the number and phenotype of the immune cells that mediate secondary damage to be more M2/anti-inflammatory. We also show that IMPs protect and preserve brain matter after TBI, and, with this neuroprotection, the neural physiology and functional behavior is greatly preserved. Furthermore, IMPs, an FDA-approved material, are biodegradable, shelf-stable, and extremely easy to administer by emergency first-responder teams which makes it a very attractive clinically translational therapeutic. Finally, we briefly describe the beginnings of a study showing novel interplay of YAP/TAZ and micro-RNAs 21 and 29b in the pathophysiology of CNS injuries using IMPs to dissect these interactions. We are currently conducting further studies to expound the mechanism of IMPs in TBI so that we can start Phase I clinical trials for the first potential disease-modifying acute intervention for TBI.
590 $a School code: 0163.
650 4 $a Neurosciences. $3 588700
650 4 $a Medicine. $3 641104
650 4 $a Molecular biology. $3 517296
653 $a Brain
653 $a Injury
653 $a Nanoparticles
653 $a Neurology
653 $a Neuroprotection
653 $a Traumatic
690 $a 0317
690 $a 0564
690 $a 0307
710 2 $a Northwestern University. $b Interdepartmental Neuroscience Program (NUIN). $3 3288838
773 0 $t Dissertations Abstracts International $g 81-07B.
790 $a 0163
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22617345